M

MRTX

Mirati Therapeut

This stock has been delisted.
News
Press Releases
Financial Reports
Profile
    Same Industry
    Name/Symbol
    Change%
    Price

    M

    Mirati Therapeut

    MRTX

    0.00%
    58.70

    R

    Regeneron Pharmaceuticals

    REGN

    +0.48%
    602.64

    E

    Entero Therapeutics

    ENTO

    -4.38%
    0.3600

    B

    BIONTECH

    BNTX

    -15.36%
    102.02

    U

    United Therapeutics Corp.

    UTHR

    -1.70%
    291.38

    V

    Vertex Pharmaceuticals Inc

    VRTX

    +0.28%
    493.84

    S

    Siga Technologie

    SIGA

    +0.31%
    6.50

    M

    Moderna

    MRNA

    -0.62%
    27.22

    C

    Charles Riv Labs Intl Inc

    CRL

    -0.95%
    114.66

    M

    Medpace Holdings

    MEDP

    -1.43%
    298.55

    T

    Talphera Inc

    TLPH

    +0.19%
    0.4860

    I

    ICON PLC

    ICLR

    -0.66%
    144.96

    C

    China Biologic

    CBPO

    --
    119.99

    I

    Iqvia Hldgs Inc

    IQV

    -0.27%
    150.28

    M

    MOLECULAR PARTNERS AG

    MOLN

    +2.92%
    4.20

    A

    Arcturus Therape

    ARCT

    +0.16%
    12.91

    G

    Gilead Sciences Inc

    GILD

    -2.81%
    103.17

    P

    PRA Health

    PRAH

    --
    165.21

    I

    Incyte Corp

    INCY

    +0.32%
    59.16

    A

    Aptevo Therapeutics Inc

    APVO

    -2.43%
    0.6748

    B

    Biospecifics

    BSTC

    +0.15%
    88.53
    Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
    During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
    More than 40M Downloads Globally : data based on Webull Technologies Limited's internal statistics as of July 14, 2023.
    Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
    Language

    English

    ©2025 Webull Securities Limited. All rights reserved.